The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer

National Cancer Institute, Naples

Status and phase: Terminated; Phase 3

Conditions: Advanced Non-Small Cell Lung Cancer

Treatments: Drug: docetaxel; Drug: vinorelbine; Drug: capecitabine; Drug: gemcitabine

Study type: Interventional

Funder types: Other

Identifiers

NCT00345059

DISTAL-2

Details and patient eligibility

About

The purpose of this study is to compare the overall survival of patients with advanced non small cell lung cancer treated with docetaxel as single therapy versus docetaxel in combination with either gemcitabine or vinorelbine or in combination with capecitabine.

Full description

This study is for patients with previously diagnosed advanced non small cell lung cancer (NSCLC, stage IIIb or IV) who had progression of their disease during or after first-line therapy containing platinum. Patients will be assigned to receive 6 cycles of therapy from one of four treatment regimens:

• docetaxel
• docetaxel + vinorelbine
• docetaxel + gemcitabine
• docetaxel + capecitabine

Enrollment: 84 patients

Sex: All

Ages: Under 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent
• Age > 18
• Histological diagnosis of non small-cell lung cancer (NSCLC)
• Stage IIIb or Stage IV disease (in IIIb, previous treatment with chemotherapy + radiotherapy, or metastatic supraclavicular lymph nodes or pleural effusion)
• Disease in progression
• Previous chemotherapy with platinum-derivative (and with > 21 days from last administration)

Exclusion criteria

• ECOG performance status > 2
• Age > 75 years
• History of malignant neoplasm within the previous 5 years (except for baso- or spino-cellular skin carcinoma and in-situ carcinoma of the uterine cervix, provided they are being adequately treated)
• Previous treatment with docetaxel
• Presence of symptomatic cerebral metastasis
• Neutrophils < 2.0 x 109/l, platelets < 100,000/l, hemoglobin > 10g/dl
• Bilirubin < 1.5 x the upper normal limit
• SGOT , SGPT, or bilirubin > 1.25 x the upper normal limits except in the presence of hepatic metastasis
• Creatinine >1.25 x the upper normal limit
• Any concomitant pathology that would, in the Investigator's opinion, contraindicate the use of the drugs in the protocol
• Inability to comply with follow up
• Pregnant or nursing females

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

84 participants in 3 patient groups

docetaxel

Active Comparator group

Description:

single agent docetaxel

Treatment:

Drug: docetaxel

docetaxel + vinorelbine OR gemcitabine

Experimental group

Description:

docetaxel in combination with either vinorelbine or with gemcitabine

Treatment:

Drug: gemcitabine

Drug: docetaxel

Drug: vinorelbine

docetaxel + capecitabine

Experimental group

Description:

docetaxel in combination with capecitabine

Treatment:

Drug: docetaxel

Drug: capecitabine